Seelos Therapeutics Inc (SEEL) Short Interest Up 106.6% in March

Seelos Therapeutics Inc (NASDAQ:SEEL) was the target of a significant increase in short interest in the month of March. As of March 29th, there was short interest totalling 1,335,610 shares, an increase of 106.6% from the March 15th total of 646,466 shares. Based on an average daily volume of 9,847,537 shares, the days-to-cover ratio is presently 0.1 days. Currently, 46.1% of the company’s stock are short sold.

Shares of SEEL opened at $3.09 on Friday. Seelos Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $17.40.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2019/04/13/seelos-therapeutics-inc-seel-short-interest-up-106-6-in-march.html.

Seelos Therapeutics Company Profile

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.

Recommended Story: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.